Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + tuvonralimab with neoadjuvant carboplatin/paclitaxel for newly diagnosed advanced epithelial ovarian cancer
ChiCTR2500101134Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Pathological complete response. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500101134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101134.